Sharifiaghdas Farzaneh, Tajalli Farzam, Otukesh Hasan, Shamsabadi Rozita Hosseini
Shahid Labbafinejad Medical Center, Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Islamic Republic of Iran.
Shahid Labbafinejad Medical Center, Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Islamic Republic of Iran.
J Pediatr Urol. 2014 Dec;10(6):1032-6. doi: 10.1016/j.jpurol.2014.02.016. Epub 2014 Apr 5.
Our aim was to evaluate the efficacy and safety of single endoscopic injection of Vantris in young girls affected by primary vesicoureteral reflux (VUR) at more than 2 years of prospective follow-up.
Over the last 4 years, 73 girls with primary VUR of grades (G) I-IV underwent a single endoscopic injection of Vantris. The mean age was 8.48 (SD=4.8) years. VUR was unilateral in 73 and bilateral in 13 patients, comprising 86 renal refluxing units (RRUs). Pre-operative evaluation consisted of: blood biochemistry, urine analysis and culture, ultrasound scan, voiding cystourethrogram (VCUG), and dimercaptosuccinic acid (DMSA) renal isotope scan. Patients were followed using ultrasound scans at 1 month and every 3 months for the first year and then 2 years after injection. Direct radionuclide cystography with technetium pertechnetate was performed at 3 and 12 months after injection. VCUG was performed only in confirmed cases of failure and downgraded VUR at 3, 12, and 24 months after endoscopic correction.
Sixty-nine (95%), 61 (83.4%), and 52 (71%) patients completed 3, 12, and 24 months' follow-up respectively. VUR was corrected and downgraded to G I in 81% and 3.3% of RRUs at 3 months' follow-up. The corrected and downgraded RRUs at 12 and 24 months' follow-up were 77%, 10%, and 77%, 11% respectively. De novo contralateral G I VUR was demonstrated in 8.6% of normal ureters. Contralateral GI VUR with normal DMSA isotope renal scans was resolved in 71% of RRUs. Febrile urinary tract infection decreased to 4.1% in the patients.
According to our study, a single Vantris injection provides a high level of efficacy and safety in the treatment of primary G I-IV VUR in young girls, at 2 years' prospective follow-up.
我们的目的是在超过2年的前瞻性随访中,评估单次内镜注射Vantris治疗原发性膀胱输尿管反流(VUR)的年轻女孩的疗效和安全性。
在过去4年中,73例I-IV级原发性VUR的女孩接受了单次内镜注射Vantris。平均年龄为8.48(标准差=4.8)岁。73例患者VUR为单侧,13例为双侧,共86个肾反流单位(RRU)。术前评估包括:血液生化、尿液分析和培养、超声扫描、排尿性膀胱尿道造影(VCUG)和二巯基丁二酸(DMSA)肾同位素扫描。患者在注射后第1个月及第一年每3个月进行超声扫描随访,之后随访2年。注射后3个月和12个月进行高锝酸盐直接放射性核素膀胱造影。仅在经内镜矫正后3、12和24个月确诊为失败和VUR降级的病例中进行VCUG。
分别有69例(95%)、61例(83.4%)和52例(71%)患者完成了3个月、12个月和24个月的随访。在3个月随访时,81%和3.3%的RRU的VUR得到矫正并降级为I级。在12个月和24个月随访时,矫正和降级的RRU分别为77%、10%和77%、11%。8.6%的正常输尿管出现新发对侧I级VUR。DMSA同位素肾扫描正常的对侧I级VUR在71%的RRU中得到缓解。患者的发热性尿路感染降至4.1%。
根据我们的研究,在2年的前瞻性随访中发现,单次注射Vantris治疗年轻女孩原发性I-IV级VUR具有较高的疗效和安全性。